Floatz logo

Tas-102

Blastic Phase Chronic Myelogenous Leukemia

National Cancer Institute (NCI)unclassifiedPhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

14 Active assets in the Blastic Phase Chronic Myelogenous Leukemia cohort.

Asset / SponsorPhaseRating
Fludarabine
Ohio State University Comprehensive Cancer Center
Phase 2BBB
TACROLIMUS
University of Michigan Rogel Cancer Center
Phase 2BB
Monomethyl Fumarate
University of Michigan Rogel Cancer Center
Phase 2BB
Imatinib
The University of Hong Kong
Phase 2BB
Nilotinib
The University of Hong Kong
Phase 2BB

View all 50 →

Same molecule, other indications

Tas-102 is also rated in:

Stage IV Renal Cell CancerDormant
BB
Indicative ·
68 / 100
View asset →
Stage IV Non-Small Cell Lung Cancer AJCC v7Dormant
BB
Indicative ·
68 / 100
View asset →
Carcinoma, Islet CellDormant
BB
Indicative ·
66 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →